基于网络药理学和实验验证探讨肾苏Ⅳ治疗糖尿病肾病的分子作用机制OA

Objective:To explore the potential mechanisms of Shensu Ⅳ in the treatment of diabetic kidney disease(DKD)through a combination of network pharmacology,molecular docking,and animal experiments.Methods:Based on the core com-ponents,target genes,and major pathways of Shensu Ⅳ predicted by network pharmacology,components,target genes,and pathways related to DKD were selected.A diabetic kidney disease rat model was established,and the effects of Shensu Ⅳ on DKD rats were observed,followed by mechanism verification of the network pharmacology results.Results:Network pharmacolo-gy results showed that among the 53 components in Shensu Ⅳ,involved 38 related targets,3 121 DKD-related target,313 inter-section targets.Key active components such as Tetraneurin A,Isoflavanone,Kaempferol,and Jaranol were identified,along with core targets including AKT serine/threonine kinase 1,epidermal growth factor receptor,steroid receptor coactivator,estrogen re-ceptor 1,and matrix metalloproteinases 9.KEGG analysis revealed that relevant pathways included the cancer pathways,metabol-ic pathways,PI3K-Akt signaling pathway,and MAPK signaling pathway.GO analysis indicated that key biological processes in-volved responses to exogenous stimuli,regulation of protein phosphorylation,and positive regulation of gene expression.Animal experiments showed that compared to the model group,the treatment group exhibited significantly reduced kidney damage under both electron microscopy and light microscopy.qRT-PCR results indicated decreased expression of AKT1 and PI3K in the treat-ment group(P<0.05).Conclusion:This study reveals that Shensu Ⅳ may exert its therapeutic effects on DKD through a multi-target,multi-pathway mechanism,providing a direction and reference for further research